Scholarlink

<p>This review aims to examine the role of probiotics in modulating the gut-derived incretin peptide axis in type 2 diabetes (T2D), with emphasis on GLP-1, related gut peptides such as GLP-2, microbial metabolite signaling, and both conventional and engineered probiotic approaches. Narrative synthesis of literature from PubMed, Scopus, and Google Scholar, using search terms such as ‘probiotics’, ‘GLP-1’, ‘type 2 diabetes’, and ‘gut microbiota’. Recent literature from 2015 to 2025 was prioritized, including randomized controlled trials, meta-analyses, systematic reviews, and relevant preclinical studies. Earlier landmark studies were included only when they established foundational mechanisms related to incretin biology, SCFA–FFAR signaling, or GLP-1 secretion physiology. Probiotics promote GLP-1 secretion via SCFAs binding to FFAR2/3 receptors, leading to improved glycemic control in meta-analyses, though with heterogeneity. Engineered probiotics like LgsGPA show superior preclinical efficacy in alleviating hyperglycemia and restoring β-cell function. While conventional probiotics offer benefits, engineered systems represent a promising advancement, requiring further clinical and regulatory development for personalized T2D therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Probiotics as modulators of the gut-derived incretin peptide axis in type 2 diabetes: GLP-1, GLP-2, and microbial metabolite signaling

  • 期刊论文

  • 发表日期：

    2026年6月30日

查看全文
  • Ghaleb Oriquat,
  • Waleed K. Abdulsahib,
  • Wael Waleed Mustafa,
  • Tushar B. Gajjar,
  • Malathi Hanumanthayya,
  • Sandeep Kumar Shukla,
  • Rajashree Panigrahi,
  • Neeraj Bainsal,
  • Saodat Khaitova

摘要

This review aims to examine the role of probiotics in modulating the gut-derived incretin peptide axis in type 2 diabetes (T2D), with emphasis on GLP-1, related gut peptides such as GLP-2, microbial metabolite signaling, and both conventional and engineered probiotic approaches. Narrative synthesis of literature from PubMed, Scopus, and Google Scholar, using search terms such as ‘probiotics’, ‘GLP-1’, ‘type 2 diabetes’, and ‘gut microbiota’. Recent literature from 2015 to 2025 was prioritized, including randomized controlled trials, meta-analyses, systematic reviews, and relevant preclinical studies. Earlier landmark studies were included only when they established foundational mechanisms related to incretin biology, SCFA–FFAR signaling, or GLP-1 secretion physiology. Probiotics promote GLP-1 secretion via SCFAs binding to FFAR2/3 receptors, leading to improved glycemic control in meta-analyses, though with heterogeneity. Engineered probiotics like LgsGPA show superior preclinical efficacy in alleviating hyperglycemia and restoring β-cell function. While conventional probiotics offer benefits, engineered systems represent a promising advancement, requiring further clinical and regulatory development for personalized T2D therapy.